Evidence map›Paper›PMID 14586411›Full record

ArticleOncogene2003

Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.

Michela Croce, Alessandro De Ambrosis, Maria V Corrias, Vito Pistoia, Marzia Occhino, Raffaella Meazza, Julien Giron-Michel, Bruno Azzarone, Roberto S Accolla, Silvano Ferrini

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Michela CroceIstituto Nazionale per la Ricerca sul Cancro, 16132 Genoa, Italy.
Alessandro De Ambrosis
Maria V Corrias
Vito Pistoia
Marzia Occhino
Raffaella Meazza
Julien Giron-Michel
Bruno Azzarone
Roberto S Accolla
Silvano Ferrini
Istituto Giannina Gaslini · ITAlleanza Contro il Cancro · ITHôpital Paul-Brousse · FRInserm · FRUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HLA class II expression is controlled by the transcriptional activator CIITA. The transcription of CIITA is controlled by different promoters, among which promoter-IV is inducible by IFN-gamma. We analysed the regulation of HLA class II molecules by IFN-gamma in a large series of human neuroblastoma cell lines. No induction of surface or intracellular HLA class II molecules and of specific mRNA was observed, in all neuroblastomas, with the exception of a nonprototypic cell line, ACN. In a large subset of neuroblastomas IFN-gamma induced expression of CIITA mRNA, derived from promoter-IV, which was not methylated. In contrast, in another subset of neuroblastomas, CIITA was not inducible by IFN-gamma and CIITA promoter-IV was either completely or partially methylated. Interestingly, the use of DNA demethylating agents restored CIITA gene transcriptional activation by IFN-gamma, but not HLA class II expression. The defect of HLA class II was not related to alterations in RFX or NF-Y transcription factors, as suggested by EMSA or RFX gene transfection experiments. In addition, the transfection of a functional CIITA cDNA failed to induce HLA class II expression in typical neuroblastoma cells. Confocal microscopy and Western blot analysis suggested a defective nuclear translocation and/or reduced protein synthesis in CIITA-transfected NB cells. Altogether, these data point to multiple mechanisms preventing HLA class II expression in the neuroblastoma, either involving CIITA promoter-IV silencing, or acting at the CIITA post-transcriptional level.

Indexed as

Nuclear ProteinsCell Line, TumorDNA-Binding ProteinsDNA MethylationGene Expression RegulationHistocompatibility Antigens Class IIHumansInterferon-gammaInterferon Regulatory Factor-1NeuroblastomaPhosphoproteinsPromoter Regions, GeneticRNA, MessengerTrans-ActivatorsTranscription FactorsTransfectionDNA-Binding ProteinsHistocompatibility Antigens Class IIInterferon-gammaInterferon Regulatory Factor-1IRF1 protein, humanMHC class II transactivator proteinNuclear ProteinsPhosphoproteinsRNA, MessengerTrans-ActivatorsTranscription FactorsUpstream Stimulatory Factors

Identifiers

PMID14586411
OpenAlexW2008928132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.